| Literature DB >> 33082911 |
Kailin Yang1,2,3, Liuting Zeng4, Anqi Ge1, Yongmei Shi2, Xiaofei Zhu2, Wenlong Liu2, Jinwen Ge2.
Abstract
BACKGROUND: Hedysarum multijugum Maxim.-Chuanxiong rhizoma compound (HCC) is a common herbal formula modified from Buyang Huanwu decoction. Clinical trials have demonstrated its therapeutic potential for ischemic stroke (IS). However, the mechanism of HCC remains unclear.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33082911 PMCID: PMC7558800 DOI: 10.1155/2020/6072380
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1The research processes.
The herb of HCC extract.
| Herb | Ratio | Place of origin | Specimen number |
|---|---|---|---|
|
| 4 | Gansu | 2014062101 |
|
| 1 | Sichuan | 2014062410 |
|
| 1.5 | Guangxi | 2014062205 |
|
| 1.5 | Zhejiang | 20140622307 |
Mobile-phase elution gradient.
| Time | A |
|---|---|
| 0 | 95 |
| 15 | 85 |
| 35 | 70 |
| 40 | 60 |
| 50 | 60 |
| 65 | 80 |
| 70 | 95 |
| 80 | 95 |
Figure 2HCC's fingerprint ((a) mixed standard and (b) HCC).
Amplification primer sequence of CHOP, GRP78, and β-actin.
| Primer | Sequence | Annealing temperature | Length |
|---|---|---|---|
| CHOP | Forward: 5-CACTCTTGACCCTGCTTCTC-3 | 60 | 116 bp |
| GRP78 | Forward: 5-GCACAGACGGGTCATTCCAC-3 | 59 | 120 bp |
|
| Forward: 5-CTCAAGAAGGAGCGGTTGGT-3 | 60 | 166 bp |
Figure 3(a) Venn diagram of potential targets and IS genes. (b) Herb-potential target network (HQ: Hedysarum multijugum Maxim.; CX: Chuanxiong rhizoma; DL: Pheretima; JC: Bombyx batryticatus).
Figure 4HCC-IS PPI network (green circle stands for HCC-IS; blue circle stands for IS genes; orange circle stands for HCC targets).
Figure 5Cluster of HCC-IS PPI network (purple circle stands for HCC-IS; blue circle stands for IS genes; pink circle stands for HCC targets).
Cluster of HCC-IS PPI network.
| Cluster | Score | Nodes | Edges | Targets and genes |
|---|---|---|---|---|
| 1 | 54.747 | 76 | 2053 | TLR2, INS, VCAM1, SERPINE1, CCR5, APOE, BCL2L1, TGFB1, VWF, NGF, TLR8, TLR7, PLG, TLR4, EDN1, CD40LG, CASP1, CASP3, CX3CL1, PPARG, CAT, HMOX1, HMGB1, CCL5, HRAS, IL18, HSPA4, PECAM1, CREB1, CYCS, IL6, JAK2, REN, TNF, ADIPOQ, IL1R1, SELE, SELP, CTLA4, IL10, MAPK1, IL1B, CSF3, MAPK14, MAPK8, ACE, SRC, ICAM1, AGT, CCR2, IL4, EGFR, ELANE, MMP1, BDNF, NLRP3, MMP2, ELN, MMP3, MMP9, SELL, AKT1, PTGS2, CD40, ALB, NOS2, NOS3, IL6R, ANXA5, VEGFA, CXCL8, TP53, MPO, SPP1, CCL2, CSF2 |
| 2 | 20.475 | 81 | 819 | IL1A, CRP, CCR3, PIK3CA, CCL11, PGF, RETN, GRB2, PGR, GSK3B, AGTR1, PLAU, TNFRSF11B, F3, ACTN4, PDGFRB, CCNA2, HPGDS, CD209, ENG, CDC42, LOX, HSP90AA1, PTPN11, PF4, CFD, IGF1, MCL1, IGF1R, IL2, SERPINF2, PPBP, RAF1, ITGAL, KNG1, NFE2L2, ITGB1, KDR, RHOA, CTSB, AIF1, KIT, LCK, LCN2, AGER, LGALS3, MAP2K1, MAPK10, NOTCH1, SOD2, SPARC, MDM2, F13A1, IL4R, MET, ADAM17, STAT1, IL13, MIF, IL1RN, MMP13, SYK, SMAD3, IL9, ESR1, TEK, MMP7, TGFB2, F8, AKT2, ALDOA, MMRN1, FCGR2A, EGF, FGF1, NR3C1, AR, CXCL12, ARG1, XIAP, CDKN2A |
| 3 | 9.714 | 64 | 306 | BACE1, GM2A, FGA, BPI, APOH, BRAF, LPA, BTK, OLR1, GSTP1, COG2, CANT1, HEXB, CASP7, CYBA, CDA, F2R, HSPA1A, HSPA8, FGB, QPCT, CHIT1, RAC1, HP, IMPDH1, IGFBP3, INSR, ASAH1, RNASE2, RNASE3, CTSG, CTSL, ITGB3, CTSS, LTA4H, LTF, SELPLG, MAN2B1, SERPINA1, ITGA2, C3, MAPT, AHSG, EIF4E, F12, MMP12, LPL, AKR1B1, F10, F11, TGM2, F2, F7, CHI3L1, FABP4, FABP5, ANG, NAMPT, FGG, ZAP70, F5, ARSA, ATIC, APOA1 |
| 4 | 8.338 | 66 | 271 | FBN1, ITIH4, LDLR, S100B, ADRA2A, BMP2, NOS1, PIK3R1, GSR, GFAP, APOB, SERPINC1, PLAT, NPY, THBD, P2RY12, PRL, CST3, MBP, PSAP, CDK2, PTK2, PTPN1, ATF6, CDK6, XBP1, MAP3K5, C5, CHEK1, DDIT3, BCL2L11, SERPIND1, PCSK9, AGTR2, ATF4, EIF2AK3, HSPA5, RBP4, ABCB1, GDNF, JAK3, TF, PROC, ALOX5, ABL1, TWIST1, ITGB2, CP, SOD1, APOA5, ERBB4, ESR2, APLNR, MMP8, TREM1, JAG1, NQO1, SAA1, CFLAR, TTR, APAF1, APOA2, VDR, PARP1, GC, PTX3 |
| 5 | 4.294 | 35 | 73 | UCP2, CTSK, CD14, ADRB2, HABP2, F13B, PDPK1, PON1, ABCA1, CETP, PIK3CG, CALCA, ADM, PLA2G7, LIPC, HCK, PROZ, SORT1, PPARA, HK1, HMGCR, BCL2, PROCR, MBL2, RAC2, APCS, G6PD, ITGA2B, CRYZ, CPB2, TFPI, CSK, ENTPD1, APOC3, PAPSS1 |
| 6 | 4 | 5 | 8 | GNPDA2, GALE, GALK1, UAP1, GNPDA1 |
| 7 | 3.667 | 7 | 11 | DHODH, MT-CO2, MT-CYB, UQCRFS1, GART, SHMT1, DHFR |
| 8 | 3.636 | 23 | 40 | ACVRL1, GLO1, PDE4B, RXRA, PDE4D, MTHFD1, PSPH, BHMT, NR1H2, TYMP, ACADM, UCK2, UMPS, HADH, NT5M, FOLH1, IVD, PNP, ARG2, OTC, ADK, GATM, AHCY |
| 9 | 3.556 | 10 | 16 | NAGS, LDHB, SORD, CLPP, ME2, SRM, ALAD, OAT, TPI1, FECH |
| 10 | 3.429 | 15 | 24 | PRKACA, GSS, TNNI3, GSTA1, GSTA3, GSTM1, NR1H4, NPPB, RARA, SMARCA4, GPX3, KAT2B, AGXT, NPPA, MTHFR |
| 11 | 3.333 | 10 | 15 | CYP4A11, CYP3A5, GSTM2, CYP4F2, CYP2J2, GSTO1, HSD17B1, STS, ADH1B, ADH1C |
| 12 | 3.333 | 7 | 10 | CYP1A1, NR1I3, NR3C2, SULT1A1, SULT1E1, CYP17A1, CYP11B2 |
| 13 | 3.333 | 7 | 10 | CYP2C19, NR1I2, RXRB, THRB, RARB, CYP2C8, RARG |
| 14 | 3.25 | 9 | 13 | GCK, IMPDH2, APRT, DTYMK, GMPR, GMPR2, TK1, PYGL, PCK1 |
| 15 | 3 | 5 | 6 | HADHA, ACADSB, PCCA, PCCB, GCDH |
| 16 | 3 | 3 | 3 | AMY1B, AMY1C, AMY1A |
| 17 | 2.889 | 10 | 13 | AURKA, PRKG1, DUT, PLK1, HTR2A, HSP90AB1, ACTA2, P2RY1, TBXA2R, MAPK12 |
| 18 | 2.5 | 9 | 10 | BID, KALRN, EDNRA, BBC3, ERN1, TXNIP, RAB5A, AVP, BAK1 |
Figure 6Bubble chart of biological processes of Cluster 4 (x-axis stands for fold enrichment).
Figure 7Herb-biological processes-target network (red diamond stands for biological processes; purple circle stands for HCC-IS; blue circle stands for IS genes; pink circle stands for HCC targets. The gray lines stand for the relationship among herbs and targets; the black lines stand for the relationships among biological processes and targets).
Figure 8Signaling pathway of HCC-IS PPI network (red diamond stands for signaling pathway; purple circle stands for HCC-IS; blue circle stands for IS genes; pink circle stands for HCC targets. The gray lines stand for the relationship among herbs and targets; the black lines stand for the relationships among pathways and targets).
Figure 9Bubble chart of the signaling pathway (x-axis stands for fold enrichment).
Figure 10The main core targets related to the endoplasmic reticulum stress.
Figure 11Neurobehavioral score (6 h after MCAO. ∗Compared with the model group, P < 0.05. #Compared with the HCC high-dose group, P < 0.05).
Figure 12Number of the neurons in unit area of hippocampal CA1 area (72 h after MCAO. ∗Compared with the model group, P < 0.05. #Compared with the HCC high-dose group, P < 0.05).
Figure 13Nissl staining in the hippocampal CA1 area (X400) (72 h after MCAO. (a) The sham operation group. (b) The model group. (c) The HCC low-dose group. (d) The HCC medium-dose group. (e) The HCC high-dose group. (f) The nimodipine group).
Figure 14Expression of GRP78 protein in each group (24 hours after intervention. (a) The sham operation group. (b) The model group. (c) The HCC low-dose group. (d) The HCC medium-dose group. (e) The HCC high-dose group. (f) The nimodipine group).
Figure 15Expression of GRP78 protein in each group (72 hours after intervention. (a) The model group. (b) The HCC low-dose group. (c) The HCC medium-dose group. (d) The HCC high-dose group. (e) The nimodipine group).
Figure 16Average gray value of GRP78 after MCAO (∗compared with the model group, P < 0.05).
Figure 17Expression of p-PERK protein in each group (24 hours after intervention. (a) The model group. (b) The HCC low-dose group. (c) The HCC medium-dose group. (d) The HCC high-dose group. (e) The nimodipine group).
Figure 18Expression of p-PERK protein in each group (72 hours after intervention. (a) The model group. (b) The HCC low-dose group. (c) The HCC medium-dose group. (d) The HCC high-dose group. (e) The nimodipine group).
Figure 19Average gray value of p-PERK after MCAO (∗compared with the model group, P < 0.05).
Figure 20Expression of CHOP protein in each group (24 hours after intervention. (a) The model group. (b) The HCC low-dose group. (c) The HCC medium-dose group. (d) The HCC high-dose group. (e) The nimodipine group).
Figure 21Expression of CHOP protein in each group (72 hours after intervention. (a) The model group. (b) The HCC low-dose group. (c) The HCC medium-dose group. (d) The HCC high-dose group. (e) The nimodipine group).
Figure 22Average gray value of CHOP after MCAO (∗compared with the model group, P < 0.05).
Figure 23The expressions of GRP78, p-PERK, and CHOP protein detected by Western blot (1: 6 h after operation in the model group; 2: 12 h after operation in the model group; 3: 24 h after operation in the model group; 4: 48 h after operation in the model group; 5: 6 h after operation in the HCC group; 6: 12 h after operation in the HCC group; 7: 24 h after operation in the HCC group; 8: 48 h after operation in the HCC group; 9: the sham operation group).
Figure 24The relative expressions of GRP78, p-PERK, and CHOP protein detected by Western blot ((a) the expression of GRP78; (b) the expression of p-PERK; (c) the expression of CHOP. ∗Compared with the model group, P < 0.05).
Figure 25The expressions of GRP78 and CHOP mRNA detected by RT-qPCR ((a) the expression of GRP78; (b) the expression of CHOP. ∗Compared with the model group, P < 0.05).